Commentary on "principal stratification - A goal or a tool?" by Judea Pearl

International Journal of Biostatistics

Volumn 7, Issue 1, 2011, Pages

  Gilbert, Peter B ^a   Hudgens, Michael G ^b   Wolfson, Julian ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

causal inference; principal stratification; vaccine trial

Indexed keywords

BIOLOGICAL MARKER; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CAUSAL EFFECT PREDICTIVENESS; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREDICTION; PRINCIPAL STRATIFICATION; REVIEW; STATISTICAL CONCEPTS; EPIDEMIOLOGY; METHODOLOGY; NOTE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL;

CAUSALITY; HUMANS; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 80053481117     PISSN: None     EISSN: 15574679     Source Type: Journal    
DOI: 10.2202/1557-4679.1341     Document Type: Review

References (32)

1. Angrist, J., G. Imbens, and D. Rubin (1996): "Identification of causal effects using instrumental variables (with comments)." Journal of the American Statistical Association, 91, 444-472.
2. Cole, S. R. and C. E. Frangakis (2009): "The consistency statement in causal inference: a definition or an assumption?" Epidemiology, 20, 3-5.
3. Daniels, M. and M. Hughes (1997): "Meta-analysis for the evaluation of potential surrogate markers." Statistics in Medicine, 16, 1965-1982. (Pubitemid 27397267)
4. Falk, L. and L. Ball (2001): "Current status and future trends in vaccine regulation." Vaccine, 19, 1567-1572. (Pubitemid 32175713)
5. Follmann, D. (2006): "Augmented designs to assess immune response in vaccine trials." Biometrics, 62, 1161-1169.
6. Frangakis, C. and D. Rubin (2002): "Principal stratification in causal inference." Biometrics, 58, 21-29. (Pubitemid 34194484)
7. Gallop, R., D. Small, J. Lin, M. Elliott, M. Joffe, and T. Ten Have (2009): "Mediation analysis with principal stratification." Statistics in Medicine, 28, 1108-1130.
8. Gilbert, P., R. Bosch, and M. Hudgens (2003): "Sensitivity analysis for the assessment of vaccine effects on viral load in HIV vaccine trials." Biometrics, 59, 531-541. (Pubitemid 37093392)
9. Gilbert, P. and M. Hudgens (2008): "Evaluating candidate principal surrogate endpoints." Biometrics, 64, 1146-1154.
10. Gilbert, P. and Y. Jin (2010): "Semiparametric estimation of the average causal effect of treatment on an outcome measured after a post-randomization event, with missing outcome data." Biostatistics, 11, 34-47.
11. Gilbert, P., L. Qin, and S. Self (2009): "Response to Andrew Dunnings comment on "Evaluating a surrogate endpoint at three levels, with application to vaccine development"," Statistics in Medicine, 28, 716-719.
12. Holland, P. (1986): "Statistics and causal inference." Journal of the American Statistical Association, 81, 945-961.
13. Hudgens, M. and M. Halloran (2006): "Causal vaccine effects on binary postinfection outcomes." Journal of the American Statistical Association, 101, 51-64. (Pubitemid 43500025)
14. Hudgens, M., A. Hoering, and S. Self (2003): "On the analysis of viral load endpoints in HIV vaccine trials." Statistics in Medicine, 22, 2281-2298. (Pubitemid 36926940)
15. Jemiai, Y., A. Rotnitzky, B. Shepherd, and P. Gilbert (2007): "Semiparametric estimation of treatment effects given base-line covariates on an outcome measured after a post-randomization event occurs." Journal of the Royal Statistical Society, Series B, 69, 879-902.
16. Joffe, M. and T. Greene (2009): "Related causal frameworks for surrogate outcomes." Biometrics, 65, 530-538.
17. Molenberghs, G., T. Burzykowski, A. Alonso, P. Assam, A. Tilahum, andM. Buyse (2008): "The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials." Journal of Statistical Planning and Inference, 138, 432-449.
18. Pearl, J. (2001): "Direct and indirect effects." Proceedings of of the 17th Conference in Uncertainty in Artificial Intelligence, 411-420.
19. Pearl, J. (2011): "Principal stratification- a goal or a tool?" The International Journal of Biostatistics, 7, Article 20.
20. Pearl, J. and E. Bareinboim (2011): "Transportability across studies: A formal approach." Technical Report, 1-33.
21. Plotkin, S. A. (2008): "Vaccines: Correlates of vaccine-induced immunity," Clinical Infectious Diseases, 47, 401-409, URL http://dx.doi.org/10.1086/589862.
22. Plotkin, S. A. (2010): "Correlates of protection induced by vaccination." Clinical Vaccine Immunology, 17, 1055-1065.
23. Prentice, R. (1989): "Surrogate endpoints in clinical trials: definition and operational criteria." Statistics in Medicine, 8, 431-440. (Pubitemid 19105891)
24. Qin, L., P. Gilbert, L. Corey, J. McElrath, and S. Self (2007): "A framework for assessing an immunological correlate of protection in vaccine trials." The Journal of Infectious Diseases, 196, 1304-1312. (Pubitemid 351412002)
25. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, and et al. (2009): "Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in thailand." New England Journal of Medicine, 361, 2209-2220.
26. Robins, J. (1986): "A new approach to causal inference in mortality studies with sustained exposure periods - application to control of the healthy worker survivor effect." Mathematical Modeling, 7, 1393-1512.
27. Robins, J. and S. Greenland (1992): "Identifiability and exchangeability of direct and indirect effects." Epidemiology, 3, 143-155.
28. Robins, J. and S. Greenland (1996): "Comment on, "Identification of causal effects using instrumental variables (with comments)"." Journal of the American Statistical Association, 91, 456-458.
29. Rubin, D. (2000): "Comment on "Causal inference without counterfactuals," by A.P. Dawid." Journal of the American Statistical Association, 95, 435-437.
30. Shepherd, B., P. Gilbert, and C. Dupont (2011): "Sensitivity analyses for comparing time-to-event outcomes only existing in a subset selected postrandomization and relaxing monotonicity." Biometrics, 67, 1100-1110.
31. VanderWeele, T. (2008): "Simple relations between principal stratification and direct and indirect effects." Statistics and Probability Letters, 78, 2957-2962.
32. Shepherd, B., P. Gilbert, and T. Lumley (2007): "Sensitivity analyses comparing time-to-event outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials." Journal of the American Statistical Association, 102, 573-582.